ClinicalTrials.gg
RecruitingNCT06895031STARUpdated Mar 6, 2026

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

A Phase 2 interventional study of JYP0015 in Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC) and Non-small Cell Lung Cancer (NSCLC), sponsored by Guangzhou JOYO Pharma Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Guangzhou JOYO Pharma Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
501st of 1,593
210 · median 100
Started
2025
with 207 others
Phase 2
650 of 1,880
273 open now
Primary completion
2026-03
later than 314 of 986 live
Registered
1,508th of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 501st largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 208 that started in 2025, is one of 650 in phase 2, reaches primary completion later than 314 of the 986 other live ones, and was the 1,508th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.

Read the detailed description

This is a Phase 1/2, multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of JYP0015 in adult patients with advanced solid tumors harboring specific RAS mutations.

The study consists of two parts:

  • Phase 1 (dose escalation) - Evaluates the safety, tolerability, and pharmacokinetic profile of JYP0015 monotherapy, preliminarily assesses efficacy, and determines the recommended dose (RD) for further evaluation.
  • Phase 2 (indication expansion) - Explores the therapeutic potential of JYP0015 monotherapy at the RD across four predefined cohorts:

    1. Pancreatic ductal adenocarcinoma (PDAC)
    2. Non-small cell lung cancer (NSCLC)
    3. Colorectal cancer (CRC)
    4. Other advanced solid tumors Phase 2 will assess both efficacy and safety within these cohorts.

JYP0015 is a potent, orally bioavailable pan-RAS inhibitor that selectively targets the active (ON) form of wild-type and mutant RAS across all three isoforms-HRAS, NRAS, and KRAS.

03

Conditions studied

  • Solid Tumor
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)

Keywords

  • PDAC
  • NSCLC
  • CRC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or pathologically confirmed solid tumors with RAS mutation via molecular tests.
  2. Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
  3. (ECOG) performance status in 0 or 1
  4. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Presence of central nervous system (CNS) ; however, subjects with previously treated may be enrolled if clinically stable.
  2. Gastrointestinal (GI) disorders that may interfere with drug administration/absorption, including but not limited to: Dysphagia or inability to swallow tablets, Malabsorption syndrome, nausea, vomiting, or diarrhea,Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)
  3. Congestive heart failure with (NYHA) functional class ≥II or (LVEF) \<50%.
  4. Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse,Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment), Familial or social circumstances that may affect patient safety, compliance, or study data collection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    JYP0015 in RAS-Mutant Solid Tumors

    This arm includes participants with histologically or pathologically confirmed advanced solid tumors harboring RAS mutations, identified via molecular testing. RAS mutations are defined as nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, 61, 117, or 146 (e.g., G12, G13, Q61, K117, or A146). Participants will receive JYP0015 as an oral tablet.

    Drug: JYP0015

Interventions

  • JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol in the dose-escalation and indication-expansion phases.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-Limiting Toxicity (DLT)

    The number of participants experiencing dose-limiting toxicities (DLT) during the dose-escalation period of the study.

    Time frame: 21 days

  2. Incidence and Severity of Treatment-Emergent Adverse Events (AEs) and Serious AEs

    The incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including abnormalities in laboratory values and vital signs.

    Time frame: Up to 3 years

  3. Overall Response Rate (ORR)

    Overall response rate assessed per RECIST v1.1 criteria.

    Time frame: Up to 3 years

Secondary outcomes

  1. Maximum Observed Blood Concentration (Cmax) of JYP0015

    Maximum plasma concentration (Cmax) of JYP0015 following administration.

    Time frame: Up to 16 weeks

  2. Time to Reach Maximum Blood Concentration (Tmax) of JYP0015

    Time to reach maximum plasma concentration (Tmax) of JYP0015 following administration.

    Time frame: Up to 16 weeks

  3. Duration of Response (DOR)

    Duration of response as assessed by RECIST v1.1.

    Time frame: Up to 3 years

  4. Time to Response (TTR)

    Time to response as assessed by RECIST v1.1.

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 11 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 26, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Mar 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895031
Lead sponsor
Guangzhou JOYO Pharma Co., Ltd
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 31, 2025
Primary completion
Mar 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 6, 2026

Study contacts

Ling Shen, M.D.
Contact
linshenpku@163.com
01088121122 ext. +86
Xiao
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pan-RAS Molecular Glue ERAS-0015

Start the discussion